deliv
polynucleotid
anim
major
challeng
face
success
therapeut
agent
given
matur
understand
antibodymedi
deliveri
techniqu
possibl
ration
design
deliveri
vehicl
circul
blood
stream
specif
deliv
target
organ
target
moieti
design
contain
cargo
rnai
mediat
without
impact
paratop
direct
deliveri
achiev
articl
review
state
art
deliveri
technolog
rna
mediat
address
techniqu
could
soon
use
enhanc
efficaci
numer
small
rna
therapeut
program
current
evalu
r
na
interfer
rnai
nobel
prize
win
phenomenon
develop
invalu
technolog
cell
biologist
character
gene
function
har
therapeut
develop
rnai
mediat
term
encompass
molecul
capabl
induc
rnai
includ
short
interf
sirna
microrna
mirna
class
polynucleotid
abil
target
mrna
cell
chang
express
level
predominantli
modul
mrna
turnov
translat
although
rnai
mediat
typic
activ
correct
cellular
compart
intrins
difficult
get
cell
extern
sourc
suscept
nucleas
rel
larg
molecular
weight
neg
charg
backbon
inabl
effici
penetr
membran
without
aid
technolog
lipid
membran
penetr
polypeptid
wide
avail
aid
deliveri
rnai
mediat
cell
cultur
techniqu
effici
deliv
rnai
mediat
anim
organ
easili
obtain
deliv
rna
cell
anim
tissu
much
complic
target
cell
typic
deepli
embed
dens
complex
microenviron
although
numer
techniqu
develop
system
deliv
rnai
mediat
major
organ
system
techniqu
lack
effici
specif
target
particular
gene
cell
type
interest
use
system
deliveri
techniqu
sever
report
suggest
often
correspond
lford
biooscientificcom
costli
rnai
mediat
deliv
wrong
locat
therapeut
indic
distribut
rnai
mediat
incorrect
locat
induc
unintend
side
effect
therefor
prefer
direct
charg
neutral
rnai
mediat
specif
cell
organ
interest
turn
focus
articl
techniqu
develop
direct
deliveri
rnai
mediat
deliv
rnai
mediat
liver
common
theme
among
mani
technolog
liver
activ
filter
function
allow
easili
target
intraven
inject
liver
import
site
metastasi
sever
diseas
target
includ
hepatitisb
viru
hepatitisc
viru
sever
gene
involv
lipid
glucos
metabol
one
first
success
gene
reduct
apolipoprotein
b
jejunum
liver
util
cholesterol
conjug
sirna
studi
util
modifi
sirna
along
liposom
formul
continu
main
strategi
liver
target
wolfrum
et
al
found
effici
uptak
sirna
conjug
depend
interact
lipoprotein
particl
receptor
transmembran
protein
studi
show
highdens
lipoprotein
direct
sirna
liver
gut
kidney
wherea
lowdens
lipoprotein
target
sirna
primarili
liver
result
illustr
nice
effect
uptak
via
common
mechan
exploit
optim
deliveri
term
deliveri
respiratori
epithelium
unformul
sirna
shown
efficaci
respiratori
infect
caus
sever
acut
respiratori
syndrom
primat
mous
model
bitko
et
al
found
nasal
administ
sirna
dose
mgkg
reduc
rsv
parainfluenza
viru
piv
titer
without
induc
interferon
respons
howev
combin
therapi
use
excess
one
sirna
inhibitori
effect
like
result
rnai
protein
mediat
competit
use
mgkg
accumul
dose
sirna
rhesu
macaqu
sever
acut
respiratori
syndrom
model
li
et
al
abl
reduc
coronaviru
induc
fever
viral
titer
acut
diffus
alveoli
damag
without
sign
sirna
induc
toxic
studi
suggest
sirna
exemplifi
new
mean
combat
emerg
respiratori
infect
progress
respiratori
tract
therapi
clinic
alnylam
begun
phase
ii
trial
sirna
target
rsv
describ
detail
follow
text
despit
unfriendli
environ
intestin
nucleic
acidbas
therapeut
sever
group
develop
uniqu
deliveri
strategi
circumv
limit
xiang
et
al
engin
escherichia
coli
transcrib
shrna
allow
success
transfer
shrna
mammalian
cell
upon
oral
intraven
administr
e
coli
encod
shrna
induc
silenc
intestin
epithelium
human
colon
cancer
xenograft
mice
studi
suggest
potenti
bacteri
transkingdommedi
rnaibas
therapi
anoth
studi
aim
treat
inflammatori
bowel
diseas
reduc
colon
inflamm
zhang
et
al
directli
administ
liposom
complex
sirna
cervicovagin
rectal
mucosa
singl
vagin
rectal
administr
reduc
correspond
mrna
level
liposom
formul
shown
nontox
elicit
interferon
respons
suggest
anoth
mean
genet
engin
gastrointestin
tract
gi
tract
vivo
two
signific
impedi
deliveri
rnai
treat
central
nervou
system
cn
diseas
system
deliveri
therapeut
across
bloodbrain
barrier
target
drug
specif
tissu
within
brain
current
preclin
clinic
studi
deliveri
rnai
cn
util
invas
intracerebr
techniqu
small
rna
therapi
direct
brain
howev
like
requir
multipl
administr
make
simpl
iv
inject
advantag
rout
deliveri
studi
success
util
monoclon
antibodi
mab
bind
endogen
transport
system
transferrin
receptor
tfr
insulin
receptor
target
antisens
agent
neuropeptid
bloodbrain
barrier
use
anoth
approach
cation
liposom
deliveri
nucleic
acid
caus
nonspecif
accumul
lung
express
brain
howev
incorpor
nucleic
acid
interior
antibodi
tether
pegyl
neutral
liposom
enabl
transport
brain
via
tfr
use
similar
techniqu
time
antibodi
epiderm
growth
factor
receptor
egfr
xia
et
al
saw
increas
surviv
time
mice
intracrani
brain
cancer
direct
deliveri
eye
pave
way
first
rnai
therapeut
human
clinic
trial
earlier
shown
success
form
intravitr
inject
cynomolgu
induc
monkey
subretin
inject
mice
studi
sirna
target
vascular
endotheli
growth
factor
vegf
use
treat
agerel
macular
degener
amd
type
deliveri
advantag
low
singl
dose
sirna
produc
high
efficaci
littl
side
effect
primat
effect
singl
sirna
dose
inject
persist
day
mice
subretin
inject
result
reduct
neovascular
compar
control
subconjunctiv
inject
also
demonstr
success
nm
sirna
target
transform
growth
factor
beta
complex
lipid
formul
led
approxim
decreas
inflammatori
cell
infiltr
postinject
human
test
reach
phase
ii
clinic
trial
describ
follow
text
develop
polynucleotid
technolog
therapeut
agent
led
food
drug
administr
fda
approv
formivirsen
phosphothio
cytomegaloviru
retin
acquir
immun
defici
syndrom
patient
give
hope
drug
similar
mechan
action
would
also
approv
unfortun
ensu
year
disappoint
regard
nevertheless
advent
rnai
number
activ
clinic
trial
therapeut
oligonucleotid
grown
enorm
accord
estim
therapeut
target
druggabl
small
molecul
proteinbas
therapi
make
rnai
mediat
attract
unlik
tradit
small
drug
proteinbas
approach
diseasecaus
gene
cell
type
tissu
potenti
target
rnai
mediat
deliveri
major
limit
march
opko
health
inc
announc
decid
termin
first
phase
iii
clinic
studi
bevasiranib
treatment
wet
amd
recommend
independ
data
monitor
committe
includ
tabl
reason
report
last
year
univers
kentucki
suggest
bevasiranib
suppress
blood
vessel
format
activ
immun
receptor
suggest
drug
effect
may
nonspecif
despit
sever
compani
still
activ
progress
rnai
technolog
clinic
trial
current
rnai
mediat
drug
develop
preclin
trial
phase
clinic
trial
phase
ii
clinic
trial
phase
iii
clinic
trial
synthet
nucleic
acid
tabl
show
list
compani
activ
rnai
mediat
drug
program
clinic
trial
review
known
compani
effort
includ
alnylam
calando
santari
alnylam
sirna
rsv
enter
phase
ii
clinic
trial
preliminari
report
promis
alnylam
rnai
therapeut
design
target
conserv
n
gene
rsv
genom
critic
replic
viru
sinc
initi
therapeut
program
alnylam
made
rapid
progress
alnylam
licens
intellectu
properti
univers
south
alabama
cover
rnai
composit
method
treat
pulmonari
viral
infect
sirna
compani
also
form
exclus
allianc
kyowa
hakko
develop
commerci
japan
major
market
asia
februari
alnylam
announc
achiev
human
proof
concept
first
industri
result
compani
gemini
trial
show
statist
signific
antivir
efficaci
gemini
random
placebocontrol
doubleblind
phase
ii
trial
healthi
adult
volunt
experiment
inocul
rsv
intranas
administ
day
day
day
prior
day
follow
viral
infect
gave
reduct
infect
rate
measur
plaqu
assay
similar
signific
reduct
measur
polymeras
chain
reaction
pcr
spinenhanc
cultur
rsv
antigen
assay
increas
number
patient
remain
free
infect
vs
placebo
viral
load
peak
viral
load
durat
viral
shed
mean
daili
viral
load
show
consist
trend
favor
treatment
effect
signific
differ
clinic
symptom
safe
well
toler
april
alnylam
initi
phase
ii
clinic
trial
assess
safeti
toler
aerosol
versu
placebo
adult
lung
transplant
patient
natur
infect
rsv
receiv
drug
administ
inhal
via
nebul
expect
deliveri
formul
commerci
secondari
object
trial
first
evalu
antivir
activ
natur
acquir
rsv
lower
respiratori
tract
infect
june
calando
pharmaceut
dose
first
patient
transferrintarget
nanoparticl
sirna
silenc
subunit
ribonucleotid
reductas
medic
consist
four
compon
includ
synthet
nonchem
modifi
sirna
cyclodextran
polym
stabil
agent
target
agent
form
approxim
nm
particl
target
agent
contain
human
transferrin
protein
cation
polym
cyclodextran
interact
electrostat
anion
sirna
assembl
nanocomplex
approxim
nm
diamet
protect
sirna
nucleas
degrad
serum
sirnacontain
nanocomplex
target
cell
overexpress
tfr
upon
reach
target
cell
transferrin
bind
tfr
cell
surfac
sirnacontain
nanocomplex
enter
cell
endocytosi
insid
cell
chemistri
built
polym
achiev
unpackag
sirna
nanocomplex
permit
function
via
rna
interfer
surfacemodifi
agent
termin
adamantan
group
form
inclus
complex
cyclodextrin
contain
polyethylen
glycol
peg
endow
particl
properti
prevent
aggreg
enhanc
stabil
enabl
system
administr
ligand
cell
surfac
receptor
coval
attach
adamantanepeg
modifi
enabl
sirnacontain
particl
target
tissu
interest
worker
caltech
children
hospit
locat
lo
angel
also
use
nanoparticl
made
calando
deliveri
system
sirna
fusion
gene
prevent
tumor
growth
dissemin
murin
model
ewe
sarcoma
treatment
made
use
femal
nonobes
diabeticsever
combin
immunodefici
nodscid
mice
inject
luciferaseexpress
human
ewe
sarcoma
cell
sirna
dose
mgkg
dose
administ
weekli
twice
week
treatment
group
contain
mice
safeti
evalu
ongo
well
addit
efficaci
studi
anim
model
pleas
refer
list
public
inform
therapeut
microrna
preclin
stage
santari
recent
began
clinic
trial
antisensebas
molecul
treatment
hepatitisc
viru
santari
use
interspers
lock
nucleic
acid
combin
along
phosphorothio
backbon
act
sequest
mirna
cytoplasm
despit
opportun
numer
challeng
mirnabas
drug
would
overcom
everi
mirna
target
multipl
gene
influenc
ten
hundr
biolog
pathway
number
safeti
concern
address
signific
anoth
issu
choos
right
mirna
target
recent
grow
bodi
evid
suggest
link
mirna
profil
cell
oncogen
potenti
lucid
pictur
role
mirna
play
cancer
like
come
forward
effort
examin
cancer
genom
reveal
number
mutat
mirna
proteincod
gene
target
sequenc
conjug
sirna
molecul
target
molecul
promis
mean
deliveri
conjug
usual
form
coval
attach
target
molecul
passeng
strand
rnai
mediat
disrupt
silenc
activ
conjug
attract
approach
wide
varieti
potenti
target
moieti
includ
nucleic
acid
peptid
aptam
cell
permeabl
peptid
antibodi
natur
molecul
cholesterol
would
expect
low
toxic
antibodybas
sirna
deliveri
activ
area
investig
immunoliposom
approach
sirnacontain
liposom
chemic
coupl
antibodi
form
immunoliposomesirna
complex
inject
complex
bind
surfac
antigen
liposom
fuse
cell
membran
deliv
sirna
cell
altern
antibodybas
approach
use
modifi
antibodyfus
protein
distinct
antigenand
rnabind
domain
theori
sirnafus
protein
complex
inject
anim
bind
target
cell
subsequ
intern
receptormedi
endocytosi
rnai
mediat
dissoci
target
deliveri
vehicl
exit
endosom
enter
cytoplasm
enter
rnai
silenc
protein
complex
use
induc
gene
silenc
take
place
fine
balanc
sirna
affin
carrier
need
sirna
releas
upon
enter
endosom
current
effort
antibodybas
sirna
deliveri
classifi
three
categori
immunoliposom
recombin
antibodi
fusion
antibodycarri
conjug
target
transport
technolog
describ
recombin
fusion
immunoconjug
rfi
distinct
antigenand
rnabind
domain
fuse
one
protein
unit
prior
deliveri
rnai
mediat
mix
rfi
form
noncoval
complex
rnabind
domain
fusion
complex
sirnarfi
complex
form
inject
anim
model
bind
target
cell
subsequ
receptormedi
endocytosi
sirna
dissoci
rfi
interact
rnainduc
silenc
complex
risc
assembl
research
paper
song
colleagu
gene
encod
nucleic
acid
bind
protein
fuse
gene
encod
fab
fragment
antibodi
direct
human
immunodefici
viru
hiv
env
protein
fabprotamin
fusion
protein
load
sirna
use
select
deliv
sirna
cell
express
env
gene
recombin
antibodyprotamin
fusion
deliv
sirna
cell
express
integrin
lymphocyt
function
associ
protein
also
shown
efficaci
use
singl
chain
antibodi
specif
fuse
shankar
group
demonstr
cell
specif
sirna
deliveri
effect
inhibit
hiv
use
antivir
sirna
report
demonstr
promis
direct
sirna
deliveri
specif
blood
cell
great
deal
excit
progress
toward
vivo
deliveri
achiev
use
recombin
immunoconjug
approach
develop
still
sever
barrier
limit
develop
small
size
rnabind
domain
limit
amount
sirna
associ
process
produc
recombin
modifi
antibodi
fusion
often
provid
low
yield
desir
product
recombin
antibodyfus
product
process
difficult
scaleup
elimin
requir
denaturationrefold
step
would
improv
product
effici
scalabl
releas
function
sirna
antibodi
lack
control
antibodycarri
conjug
made
commerci
avail
antibodi
potenti
deliveri
platform
chemic
conjug
one
posit
charg
rnai
mediat
bind
domain
onto
antibodi
increas
rnai
load
capac
least
rnai
mediat
per
conjug
enabl
larger
quantiti
rnai
mediat
enter
cytoplasm
model
system
mani
studi
bioo
scientif
perform
conjug
human
epiderm
growth
factor
receptor
antibodi
erbb
famili
receptor
tyrosin
kinas
protein
includ
egfr
cell
membran
receptor
compos
extracellular
ligandbind
domain
transmembran
lipophil
domain
intracellular
tyrosin
kinas
domain
phosphoryl
tyrosin
kinas
domain
follow
homodimer
differ
receptor
famili
lead
protein
activ
promot
signal
cascad
includ
promot
cell
growth
also
studi
uptak
specif
sirna
cell
cultur
anim
tumor
model
order
determin
antibodi
conjug
deliv
sirna
target
cell
incub
antibodi
conjug
sirna
vari
molar
ratio
appli
complex
cell
plate
onto
cover
slip
studi
antibodi
conjug
shown
deliv
sirna
cell
line
express
cell
line
lack
receptor
antibodi
lack
sirna
cellular
uptak
suggest
antibodi
conjug
sirna
carri
enter
cell
vivo
sirna
deliveri
efficaci
immunoconjug
test
system
inject
nodscid
mice
silenc
glyceraldehyd
dehydrogenas
gapdh
express
tumor
cell
overexpress
target
antigen
perform
anim
test
use
antibodi
conjug
tumor
made
cell
line
express
breast
cancer
cell
line
contain
significantli
low
level
receptor
nodscid
mice
inject
subcutan
either
million
cell
flank
monitor
postinject
tumor
format
tumor
reach
suffici
size
sirna
treatment
use
antibodi
conjug
deliveri
vehicl
commenc
mix
antibodi
conjug
either
gapdh
sirna
negativecontrol
sirna
inject
tumor
twice
interv
inject
seventytwo
hour
follow
inject
mice
sacrif
tumor
remov
process
analyz
knockdown
use
gapdh
enzymelink
immunosorb
assay
elisa
data
illustr
figur
suggest
antibodi
conjug
may
deliv
sirna
load
knockdown
gapdh
cell
express
effect
use
rnai
mediat
therapi
current
depend
avail
deliveri
vehicl
system
administ
target
particular
cell
limit
side
effect
nake
rnai
mediat
deliv
bloodstream
halfliv
order
minut
renal
clearanc
addit
serum
nucleas
recogn
doubl
strand
rna
serum
rnase
degrad
sirna
overcom
challeng
rnai
mediat
mix
antibodycontain
liposom
peptid
target
iv
deliveri
anim
model
cancer
work
effect
system
yet
target
sirna
deliveri
system
follow
characterist
rnai
mediat
must
protect
blood
stream
prolong
halflif
transport
must
occur
across
endotheli
wall
must
specif
bind
cell
plasma
membran
activ
endocytosi
cell
rnai
mediat
must
activ
target
cell
elicit
desir
biolog
xenograft
tumor
cell
use
receptormedi
sirna
deliveri
ad
gapdh
sirna
scrambl
negativecontrol
sirna
ng
antibodi
conjug
complex
incub
min
room
temperatur
inject
directli
xenograft
tumor
made
use
either
cell
line
seventytwo
hour
postinject
anim
sacrif
tumor
remov
analyz
use
inhous
gapdh
elisa
assay
rel
gene
reduct
compar
scrambl
neg
control
determin
circular
panel
illustr
xenograft
tumor
gener
nodscid
mice
deliveri
conjug
respons
current
avail
rnai
mediat
deliveri
technolog
espous
characterist
sever
studi
come
close
develop
tumor
select
deliveri
system
schiffel
et
al
attach
arginineglycineaspart
acid
rgd
peptid
ligand
distal
end
peg
mean
target
tumor
neovasculatureexpress
integrin
pegyl
polyethyleneimin
pei
complex
sirna
tail
vein
inject
tumorbear
mice
show
select
uptak
inhibit
tumor
angiogenesi
growth
rate
complex
shown
improv
serum
stabil
h
compar
unformul
rnai
mediat
use
similar
approach
kim
et
al
util
peigraftpegfol
deliv
sirna
target
green
fluoresc
protein
gfp
folat
receptor
overexpress
keratinform
tumor
cell
line
kb
cell
result
demonstr
success
target
reduct
cytoplasm
build
premis
integrintarget
rnai
mediat
deliveri
peer
et
al
develop
liposom
base
integrintarget
sirna
vehicl
target
specif
leukocyt
subset
gut
inflamm
use
stabil
unilamellar
vesicl
ulv
coval
attach
hyaluronan
palmitoylphosphatidylethanolamin
dppe
ulv
stabil
particl
system
circul
endocytosi
monoclon
antibodi
integrin
coval
attach
hyaluronan
system
applic
silenc
leukocyt
revers
induc
coliti
mice
suppress
leukocyt
prolifer
helper
cell
cytokin
express
coval
conjug
perform
peer
et
al
typic
perform
reactiv
site
carri
head
group
phospholipid
use
crosslink
intermediari
conjug
may
perform
homobifunct
heterobifunct
crosslink
reagent
carbodiimid
reduct
amin
nhydroxysuccinimid
nh
ester
activ
carboxyl
noncoval
use
avidinbiotin
interact
stabil
vivo
use
complex
often
depend
size
liposom
particl
amount
antibodi
reaction
mole
amount
lipid
bilay
formul
use
liposomalantibodi
conjug
demonstr
pirollo
et
al
specif
deliv
sirna
primari
metastat
tumor
includ
prostat
pancreat
breast
tumor
system
administr
pirollo
et
al
util
tfrscfvliposom
complex
deliv
sirna
liposom
encapsul
sirna
cation
dotap
dioleoyl
phosphatidylethanolamin
dope
lipid
label
antitfrscfv
target
moieti
tfr
level
shown
correl
prolif
natur
tumor
cell
recycl
intern
rapidli
divid
cancer
cell
contribut
uptak
tfrtarget
liposom
complex
sirna
reach
intend
target
must
releas
endosom
knockdown
gene
interest
often
limit
efficaci
mani
studi
incorpor
ph
sensit
compon
liposom
develop
tri
enhanc
effici
liposom
payload
exploit
fact
endosom
compart
gener
acid
natur
destabil
target
liposom
follow
acidif
enhanc
inclus
dope
undergo
lamellar
hexagon
phase
transit
low
ph
releas
captur
liposom
compon
ph
sensit
peptid
attach
liposom
neutral
ph
bind
adjac
bilay
acid
ph
util
latter
approach
chen
et
al
aoki
et
al
develop
histidinelysin
polym
shown
disrupt
endosom
increas
transfect
effici
unmodifi
cation
liposom
use
liposom
contain
sirna
label
polym
adapt
studi
pirollo
et
al
demonstr
tumor
specif
deliveri
result
nearcomplet
knockdown
express
tumor
show
size
reduct
xenograft
tumor
use
technolog
field
sirna
like
rapid
progress
technolog
propel
vitro
cell
cultur
studi
advanc
clinic
trial
year
data
preclin
program
suggest
sirna
therapeut
potenti
treat
diseas
mani
preclin
studi
led
ongo
clinic
trial
encourag
preliminari
result
despit
progress
deliveri
remain
largest
obstacl
improv
sirna
therapi
understand
rnabas
therapi
deliv
tissu
affect
diseas
essenti
wide
success
treat
diseas
current
clinic
trial
util
direct
inject
organ
target
administr
unmodifi
sirna
sirna
minor
chemic
modif
direct
inject
target
administr
remain
best
option
sirna
deliveri
today
unlik
sirnabas
therapeut
limit
approach
broad
yet
target
system
clinic
treatment
like
futur
safe
efficaci
human
applic
move
direct
multipl
deliveri
technolog
requir
evolv
base
uniqu
challeng
organ
diseas
may
pose
propos
antibodymedi
deliveri
vehicl
lead
way
direct
sirna
target
assumpt
base
previou
success
obtain
use
antibodi
treat
diseas
practic
standpoint
antibodi
design
target
cellular
surfac
antigen
specif
fashion
antibodi
also
engin
impact
immun
system
human
antibodi
drug
conjug
mylotarg
alreadi
approv
fda
use
treat
human
diseas
factor
well
other
make
antibodybas
method
drug
deliveri
attract
